Merck & Co., Inc. (MRK) Shares Sold by Bourgeon Capital Management LLC

Bourgeon Capital Management LLC lessened its position in Merck & Co., Inc. (NYSE:MRK) by 9.9% in the 4th quarter, HoldingsChannel reports. The fund owned 95,672 shares of the company’s stock after selling 10,548 shares during the period. Merck & Co., Inc. makes up approximately 4.8% of Bourgeon Capital Management LLC’s investment portfolio, making the stock its biggest holding. Bourgeon Capital Management LLC’s holdings in Merck & Co., Inc. were worth $7,310,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of MRK. Bank of New York Mellon Corp lifted its position in shares of Merck & Co., Inc. by 184,252.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 38,985,039 shares of the company’s stock valued at $2,765,600,000 after acquiring an additional 38,963,892 shares in the last quarter. Capital International Investors lifted its position in shares of Merck & Co., Inc. by 178.2% in the 3rd quarter. Capital International Investors now owns 32,984,606 shares of the company’s stock valued at $2,339,928,000 after acquiring an additional 21,127,887 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Merck & Co., Inc. by 64.3% in the 3rd quarter. Janus Henderson Group PLC now owns 20,519,549 shares of the company’s stock valued at $1,455,653,000 after acquiring an additional 8,032,634 shares in the last quarter. Matthew Goff Investment Advisor LLC lifted its position in shares of Merck & Co., Inc. by 5,970.0% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 5,369,519 shares of the company’s stock valued at $88,460,000 after acquiring an additional 5,281,059 shares in the last quarter. Finally, Senator Investment Group LP purchased a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at approximately $285,594,000. Institutional investors and hedge funds own 74.29% of the company’s stock.

In other news, Director Thomas H. Glocer sold 10,000 shares of the stock in a transaction on Monday, February 4th. The shares were sold at an average price of $75.96, for a total transaction of $759,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Kenneth C. Frazier sold 231,566 shares of the stock in a transaction on Tuesday, February 5th. The stock was sold at an average price of $78.08, for a total transaction of $18,080,673.28. Following the transaction, the chairman now owns 923,516 shares in the company, valued at approximately $72,108,129.28. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 244,618 shares of company stock worth $19,075,949. 0.32% of the stock is currently owned by company insiders.

MRK has been the subject of several research analyst reports. SunTrust Banks upped their price target on shares of Merck & Co., Inc. from $77.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, October 29th. Citigroup upped their price target on shares of Merck & Co., Inc. from $79.00 to $84.00 and gave the company a “buy” rating in a research report on Wednesday, October 31st. Zacks Investment Research downgraded shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 24th. BMO Capital Markets downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 price target for the company. in a research report on Wednesday, January 23rd. Finally, Morgan Stanley set a $81.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, December 20th. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Merck & Co., Inc. presently has a consensus rating of “Buy” and a consensus target price of $73.15.

Merck & Co., Inc. stock opened at $79.02 on Thursday. The company has a market capitalization of $209.82 billion, a price-to-earnings ratio of 18.21, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a current ratio of 1.44, a quick ratio of 1.15 and a debt-to-equity ratio of 0.61. Merck & Co., Inc. has a twelve month low of $52.83 and a twelve month high of $80.19.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Friday, February 1st. The company reported $1.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.01. The firm had revenue of $11 billion for the quarter, compared to analyst estimates of $10.93 billion. Merck & Co., Inc. had a net margin of 14.71% and a return on equity of 35.10%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.98 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 4.65 earnings per share for the current year.

Merck & Co., Inc. declared that its Board of Directors has approved a stock buyback program on Thursday, October 25th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 5.1% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be paid a dividend of $0.55 per share. The ex-dividend date is Thursday, March 14th. This represents a $2.20 annualized dividend and a dividend yield of 2.78%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 50.69%.

COPYRIGHT VIOLATION WARNING: “Merck & Co., Inc. (MRK) Shares Sold by Bourgeon Capital Management LLC” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.chaffeybreeze.com/2019/02/14/merck-co-inc-mrk-shares-sold-by-bourgeon-capital-management-llc.html.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: What is Cost of Debt?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply